Thorne HealthTech, Inc.
Thorne HealthTech, Inc. (Nasdaq: THRN), relating to its proposed sale to L. Catterton. Under the terms of the agreement, THRN shareholders are expected to receive $10.20 in cash per share they own.
Thorne HealthTech, Inc. (Nasdaq: THRN), relating to its proposed sale to L. Catterton. Under the terms of the agreement, THRN shareholders are expected to receive $10.20 in cash per share they own.
Abcam plc. (Nasdaq: ABCM), relating to its proposed sale to Danaher Corp. Under the terms of the agreement, ABCM shareholders are expected to receive $24.00 in cash per share they own.
Hersha Hospitality Trust (NYSE: HT), relating to its proposed sale to affiliates of KSL Capital Partners, LLC. Under the terms of the agreement, HT shareholders are expected to receive $10.00 in cash per share they own
RPT Realty (NYSE: RPT), relating to its proposed merger with Kimco Realty. Under the terms of the agreement, RPT shareholders are expected to receive 0.6049 shares of Kimco per share they own.
Summit Financial Group, Inc. (Nasdaq: SMMF), relating to its proposed merger with Burke & Herbert Financial Services Corp. Under the terms of the agreement, SMMF shareholders are expected to own 50% of the combined company.
Earthstone Energy, Inc. (NYSE: ESTE), relating to its proposed merger with Permian Resources Corp. Under the terms of the agreement, ESTE shareholders will receive 1.446 shares of Permian per share they own.
PhenomeX Inc. (Nasdaq: CELL), relating to its proposed sale to Bruker Corp. Under the terms of the agreement, CELL shareholders will receive $1.00 in cash per share they own.
Crestwood Equity Partners LP (NYSE: CEQP), relating to its proposed sale to Energy Transfer LP. Under the terms of the agreement, CEQP shareholders will receive 2.07 shares of Energy Transfer per share they own.
Holly Energy Partners, L.P. (NYSE: HEP), relating to its proposed sale to HF Sinclair Corp. Under the terms of the agreement, HEP shareholders are expected to receive 0.315 shares of HF Sinclair common stock and $4.00 in cash per share they own.
Timber Pharmaceuticals, Inc. (NYSE: TMBR), relating to its proposed sale to LEO Pharma A/S.